Trials / Completed
CompletedNCT03235570
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
A Phase 1, Open-Label, Dose-Escalation, Dose-Expansion, Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of pemigatinib in Japanese subjects with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemigatinib | Pemigatinib at the protocol-defined dose administered once daily. |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2020-03-04
- Completion
- 2020-03-04
- First posted
- 2017-08-01
- Last updated
- 2020-05-29
Locations
12 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03235570. Inclusion in this directory is not an endorsement.